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NICE has renewed accreditation of the process used by the British Association of 
Dermatologists to produce clinical guidelines. The renewed accreditation is valid until 31 
May 2021 and applies to guidance produced using the processes described in Updated 
guidance for writing a British Association of Dermatologists clinical guideline – the 
adoption of the GRADE methodology 2016. The original accreditation term began on 12 
May 2010. More information on accreditation can be viewed at 
www.nice.org.uk/accreditation.  
 
PURPOSE AND SCOPE OF THE GUIDELINE 
The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic 
therapies (adalimumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab) in adults, 
children and young people for the treatment of psoriasis; consideration is given to the specific needs of 
people with psoriasis and psoriatic arthritis. Biologic therapies have now been in use for over 10 years, and 
with accrued patient-years exposure and clinical experience, many areas that were covered in previous 
versions of the guideline are now part of the Summary of Product Characteristics (SPC) and/or routine care 
so that specific recommendations are redundant (see Toolkit A: Summary of licensed indications and 
posology for biologic therapy, in Supporting information 2). Therefore, in this update we focus on areas 
where there has been a major change in the evidence base or clinical practice, where practice is very varied 
and/or where clear consensus or guidelines are lacking (see section 3.1 in Supporting information 1). 
 
This set of guidelines has been developed using the BAD’s recommended methodology1 with reference to 
the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument [www.agreetrust.org]2 and the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE).3 Recommendations were 
developed for implementation in the NHS (U.K.). Note that the guideline recommendations will normally 
fall within licensed indications; exceptionally, and only if clearly supported by evidence, use outside a 
licensed indication may be recommended. The guideline assumes that prescribers cross-reference a drug’s 
SPC to inform clinical decision-making for individual patients. Where relevant, this guidance applies to 
biosimilars (similar biological medical products), subject to recommendations given within the BAD position 
statement4 and EMA guidelines.5 This guidance does not cover agents licensed outside the UK or use of 
biologic therapies for indications other than psoriasis or use when psoriatic arthritis is the main indication. 
 
To aid implementation, this executive summary contains only key clinical findings and recommendations 
(see Table 2) derived from systematic review of the evidence. The strength of recommendation is 
expressed by the wording and symbols featured in Table 1. Good practice point (GPP) recommendations 
are derived from informal consensus. A decision aid, informed by the evidence reviews, has been 
developed to help patients and clinicians choose the appropriate biologic therapy (see Table 3) and a 
suggested schedule for screening and monitoring (see Table 4) is also provided. The full version of the 
guideline is available online (Supporting information 1) and includes details on methodology, six systematic 
reviews with appraisal and discussion of the clinical evidence. 
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Strength Wording Symbols Definition 
Strong 
recommendation for 
the use of an 
intervention 
“Offer”  
(or similar, e.g. 
“Provide”, 
“Advise”, 
“Screen”, etc.) 
 
Benefits of the intervention outweigh the risks; most 
patients would choose the intervention whilst only a 
small proportion would not; for clinicians, most of their 
patients would receive the intervention; for policy 
makers, it would be a useful performance indicator. 
Weak 
recommendation for 
the use of an 
intervention “Consider”  
Risks and benefits of the intervention are finely 
balanced; many patients would choose the intervention 
but many would not; clinicians would need to consider 
the pros and cons for the patient in the context of the 
evidence; for policy makers, it would be a poor 
performance indicator where variability in practice is 
expected. 
No recommendation Θ Insufficient evidence to support any recommendation. 
Strong 
recommendation 
against the use of an 
intervention 
“Do not offer”  
Risks of the intervention outweigh the benefits; most 
patients would not choose the intervention whilst only a 
small proportion would; for clinicians, most of their 
patients would not receive the intervention. 
Table 1. Strength of recommendation ratings 
  
SUMMARY OF RECOMMENDATIONS 
The evidence- and consensus-based (GPP) recommendations listed in Table 2 below should be 
implemented in the context of the evidence and discussions in the full version of the guideline.  
 
                                                          
I
 http://www.badbir.org/ 
II
 Please see NICE guidelines CG153 for more information on contraindications and reviewing treatment response to 
phototherapy and systemic therapy  
Recommendations Strength 
Using biologic therapy 
R1 Initiation and supervision of biologic therapy for people with psoriasis should be 
undertaken by specialist physicians experienced in the diagnosis and treatment of 
psoriasis. Routine monitoring may be delegated to other healthcare professionals, for 
example, clinical nurse specialists.  Manage psoriatic arthritis and/or multi-morbidity in 
consultation with the relevant healthcare professionals. 
 
R2 
 
Agree and formalise arrangements for drug administration, monitoring and follow-up 
between health carers and the person receiving treatment 
 
R3 Offer people with psoriasis who are starting biologic therapy the opportunity to 
participate in long-term safety registries (in the U.K. and Republic of Ireland the British 
Association of Dermatologists Biologic Interventions Register, BADBIRI ) 
 
Criteria for biologic therapy 
 
R4 
Offer biologic therapy to people with psoriasis requiring systemic therapy if methotrexate 
and ciclosporin have failed, are not tolerated or are contraindicatedII and the psoriasis has 
a large impact on physical, psychological or social functioning (for example, a DLQI or 
cDLQI of >10 or clinically relevant depressive or anxiety symptoms) and one or more of 
 
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III
 Physician’s global assessment clear, nearly clear, mild, moderate, severe, very severe 
IV
 Please see http://pathways.nice.org.uk/pathways/musculoskeletal-conditions#content=view-node%3Anodes-
psoriatic-arthritis&path=view%3A/pathways/musculoskeletal-conditions/arthritis.xml 
V
 Rapid relapse is defined as greater than 50% of baseline disease severity within 3 months of completion of any 
treatment (for example narrow band UVB) 
VI
 www.medicines.org.uk/emc/ 
VII
 http://www.bad.org.uk/healthcare-professionals/forms-downloads 
 
the following disease severity criteria apply: 
 the psoriasis is extensive (defined as BSA >10%, or a PASI ≥10, or at least 
‘moderate’ on physician’s global assessmentIII) 
 the psoriasis is severe at localised sites and associated with significant functional 
impairment and/or high levels of distress (for example nail disease or 
involvement of high-impact and difficult-to-treat sites such as the face, scalp, 
palms, soles, flexures and genitals) 
R5 Consider biologic therapy earlier in the treatment pathway (for example, if methotrexate 
has failed, is not tolerated or is contra-indicated) in people with psoriasis that fulfils the 
disease severity criteria and who also have active psoriatic arthritisIV or who have 
psoriasis that is persistent (i.e. that relapses rapidly off a therapy that cannot be 
continued long-termV) 
 
Prescribing biologic therapy 
R6 Be aware of the benefits of, contraindications to and adverse effects associated with 
biologic therapies and reference the drug-specific SPCsVI  
 
R7 Provide high-quality, evidence-based information to people being prescribed biologic 
therapies.   Explain the risks and benefits to people undergoing this treatment (and their 
families or carers where appropriate), using absolute risks and natural frequencies when 
possible (see Table 3: Decision aid).  Allow them adequate time to consider the 
information. 
 
 
R8 Support and advice should be offered to people with psoriasis (and their families or carers 
where appropriate) by healthcare professionals who are trained and competent in the 
use of biologic therapies 
 
Reviewing biologic therapy 
R9 Assess initial response to biologic therapy in people with psoriasis at time points 
appropriate for the drug in question, and then on a regular basis during therapy (for 
example, every 6 months)  
 
R10 Review response to biologic therapy by taking into account: 
 psoriasis disease severity compared with baseline (for example, Psoriasis Area 
and Severity Index [PASI] baseline to endpoint scoreVII) 
 the agreed treatment goal  
 control of psoriatic arthritis disease activity and/or inflammatory bowel disease 
(in consultation with a rheumatologist and/or gastroenterologist) 
 the impact of psoriasis on the person's physical, psychological and social 
functioning 
 the benefits versus the risks of continued treatment 
 the views of the person undergoing treatment (and their family or carers, where 
appropriate) 
 adherence to the treatment 
 
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R11 Assess whether the minimal response criteria have been met, as defined by: 
 a 50% or greater reduction in baseline disease severity (for example, PASI 50 
response, or % BSA where the PASI is not applicable) and  
 clinically relevant improvement in physical, psychological or social functioning 
(for example, a 4-point or greater improvement in DLQI or resolution of low 
mood) 
 
R12 Consider changing to an alternative therapy, including another biologic therapy, if any of 
the following applies: 
 the psoriasis does not achieve the minimum response criteria (primary failure – 
see R11)  
 the psoriasis initially responds but subsequently loses this response (secondary 
failure) 
 the current biologic therapy cannot be tolerated or becomes contraindicated 
 
Choice of biologic therapy: general considerations 
R13 Take into account both psoriasis and psoriatic arthritis before initiating or making 
changes to biologic therapy, and: 
 manage treatment in consultation with a rheumatologist or paediatric 
rheumatologist 
 be aware that the presence of and phenotype of psoriatic arthritis (for example, 
peripheral versus axial disease) may influence access to, choice and dose of, 
biologic therapy 
 
R14 Tailor the choice of agent to the needs of the person and take into account the following 
factors (see Table 3: Decision aid):  
 
Psoriasis factors 
the goal of therapy (for example a PGA of clear or nearly clear) 
disease phenotype and pattern of activity  
disease severity and impact  
the presence of psoriatic arthritis (in consultation with an adult or paediatric 
rheumatologist) 
outcomes to previous treatments for psoriasis 
  
Other factors 
person's age 
past or current co-morbid conditions (for example, inflammatory bowel disease, 
cardiovascular disease) 
conception plans 
body weight  
the person's views and any stated preference on administration route or frequency 
adherence 
 
 
R15 Be aware that the recommended first-line choice of biologic therapy will not be 
appropriate for every individual; use the decision aid and with reference to R14 to inform 
choice of alternative licensed biologic therapies. 
 
Choice of biologic therapy in adults: first line 
R16 Offer ustekinumab as a first-line biologic agent to adults with psoriasis who fulfil the 
criteria for biologic therapy (see also R4 and R5) 
 
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VIII
 ‘Very severe’ relates to the physician’s global assessment or/and the NICE definition ((PASI 20 or more and DLQI 18 
or more) and failed to respond to standard systemic therapies such as ciclosporin, methotrexate or PUVA (psoralen 
and long-wave ultraviolet radiation), or the person is intolerant to or has a contraindication to these treatments.) 
IX
 Off-licence 
R17 Offer adalimumab as a first-line biologic agent to adults with psoriasis particularly when 
psoriatic arthropathy is a consideration  
 
R18 Consider secukinumab as a first-line biologic agent in adults with psoriasis, with or 
without psoriatic arthritis  
 
Choice of biologic therapy in adults: second line 
R19 Offer any of the currently licensed biologic therapies when psoriasis has not responded to 
a first biologic therapy. Use the decision aid (Table 3) and take into account all factors 
detailed in R14 to select the most appropriate agent. 
 
Consideration 
R20 Reserve infliximab for use in people with very severe diseaseVIII or where other available 
biologic agents have failed or cannot be used 
 
What to do when a second or subsequent biologic therapy fails in adults 
R21 When a person’s psoriasis responds inadequately to a second or subsequent biologic 
agent seek advice from a clinician with expertise in biologic therapy and consider any of 
the following strategies: 
 reiterate advice about modifiable factors contributing to poor response (for 
example, obesity and poor adherence) 
 optimise adjunctive therapy (for example, switch from oral to sub-cutaneous 
methotrexate) 
 switch to an alternative biologic agent 
 consider non-biologic therapy approaches (for example inpatient topical therapy, 
phototherapy or standard systemic therapy) 
 
When to consider dose escalation 
R22 Consider escalating the dose of biologic therapy in adults, where this is feasible and 
funded (see table below) when an inadequate primary response may be due to 
insufficient drug dosing (for example, in people who are obese or whose psoriasis 
relapses during the treatment cycle). Take into account that this may be associated with 
an increased risk of infection, and, depending on the drug, off-licence. 
 
Biologic agent  Suggested dose-escalation strategy 
Ustekinumab 45 mg every 12 weeks 
(<100 kg) 
Ustekinumab 90 mg every 12 weeks 
(<100 kg)IX 
Ustekinumab 90 mg every 12 weeks 
(>100 kg) 
Ustekinumab 90 mg every 8 weeks 
(>100 kg)IX 
Adalimumab 40 mg every other week Adalimumab 40 mg weekly 
Etanercept 50 mg once weekly Etanercept 50 mg twice weekly 
Infliximab 5 mg/kg every 8 weeks Infliximab 5 mg/kg every 6 weeksIX 
 
 
Choice of biologic therapy in children and young people 
R23  Offer adalimumab ( 4 years), etanercept ( 6 years) or ustekinumab ( 12 years) to 
children and young people who fulfil the criteria for biologic therapy (see also R4 and R5) 
 
R24 When a child’s or young person’s psoriasis responds inadequately to a first or subsequent  
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X
 Major congenital malformations reported in 3.6-5.0% of women exposed to anti-TNF compared with 1.5-4.7% in 
control groups (odds ratios [OR] = 1.32-1.64) 
biologic agent seek advice from a clinician with expertise in biologic therapy and consider 
any of the following strategies: 
 reiterate advice about modifiable factors contributing to poor response (for 
example, obesity and poor adherence) 
 optimise adjunctive therapy (for example, switch from oral to sub-cutaneous 
methotrexate) 
 switch to an alternative biologic agent 
 consider non-biologic therapy approaches (for example inpatient topical therapy 
or standard systemic therapy) 
Transitioning to/between biologic therapies 
R25  When choosing the transitioning strategy from one drug therapy to another and whether 
a therapy washout (or no washout) should be used, take into consideration: 
 the pharmacology of the drugs that are being started and stopped (see Toolkit A: 
Summary of licensed indications and posology for biologic therapy, in Supporting 
information 2)  
 the person’s clinical circumstances  
 the person’s views on the risks and benefits of transitioning option(s)  
 
R26 Consider the following strategies when transitioning from standard systemic to biologic 
therapy:  
 in stable disease, aim to allow 1 month to elapse between the last dose of any 
current standard systemic immunosuppressant psoriasis therapy (except 
methotrexate) and the planned date of biologic initiation 
 start a biologic therapy with no drug washout period in people taking 
methotrexate, or in people on other therapies where this would lead to unstable 
disease  
 when standard, systemic immunosuppressant therapy cannot be stopped (for 
example, in people for whom a disease flare would be severe or hazardous), 
rationalise use of therapy and stop as soon as possible (for example, when a 
minimum response has been achieved)  
 
R27 When transitioning to a new biologic therapy (from a previous biologic therapy) consider 
using a 1-month washout period, or the length of the treatment cycle (whichever is 
longer), between the last dose of the current biologic therapy and the planned date of 
biologic initiation 
 
Conception and pregnancy 
R28 Provide information about the possible effects of biologic therapy during conception and 
pregnancy including: 
 the importance of controlling severe or unstable psoriasis to maintain maternal 
health 
 that most pregnancies reported in women taking biologic therapy at conception 
and during pregnancy have successful outcomes 
 that evidence about the effect of biologic therapy on conception and pregnancy 
mostly relates to TNF antagonists in women with rheumatological and 
inflammatory bowel disease; this evidence indicates a potential risk associatedX 
 
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XI
 For example, http://www.medicinesinpregnancy.org/Medicine--pregnancy 
XII
 There are no known interactions between biologic therapies and contraceptive methods (see drug-specific SPCs) 
with exposure to TNF antagonists but is of low quality, and may relate to other 
factors (for example, other co-therapies or the underlying disease) 
that the risk of fetal abnormalities in women with psoriasis who conceive on 
biologic therapy has not been adequately studied and therefore cannot be 
quantified 
 that maternal IgG, and therefore biologic drugs currently licensed for psoriasis, 
are actively transferred to the developing fetus during the second and third 
trimester and that the impact of this on fetal and neonatal development and risk 
of infection has not been adequately studied 
 that live vaccines must be avoided in infants born to mothers taking biologic 
therapy beyond 16 weeks’ gestation 
 relevant patient information resourcesXI 
R29 Advise women of child-bearing potential who are starting biologic therapy for psoriasis to 
use effective contraceptionXII and discuss conception plans with the consultant 
supervising their care (see R30) 
 
R30 Discuss the risks and benefits of continuing versus stopping biologic therapy with women 
who are of child-bearing potential or who become pregnant. Offer advice on a case-by-
case basis by taking into account the woman’s views and the:  
 course of psoriasis disease and the fetal outcome during any prior pregnancies 
 risk of severe or unstable psoriasis if the biologic therapy were stopped 
 physical, psychological and social functioning if the biologic therapy were stopped 
 options for alternative, non-biologic treatment strategies 
 
R31 Assess whether biologic therapy for psoriasis can be stopped in women who become 
pregnant. Ensure consultation and information-sharing across specialities including with 
an obstetrician who has expertise in caring for pregnant women with medical problems. 
Collect pregnancy outcome data for safety registries, for example BADBIR in the U.K. and 
Republic of Ireland. 
 
R32 Advise mothers who have received biologic therapy for psoriasis beyond 16 weeks’ 
gestation that their infants should not receive any live vaccinations until they have 
reached 6 months of age (for example, rotavirus and BCG) 
 
Biologic therapy and cancer risk 
R33 Assess people with psoriasis prior to, and during treatment with, biologic therapy with 
respect to: 
 their past or current history of cancer (see R35) and/or  
 any future risk of cancer 
 
R34 Provide information to people with psoriasis about the importance of participating in 
national cancer screening programmes  
 
R35 Exercise caution and discuss with the relevant cancer specialist when prescribing biologics 
in people with psoriasis and:  
 a history of cancer, particularly if this has been diagnosed and treated <5 years 
previously and/or  
 where the baseline risk of skin cancer is increased (for example, previously 
treated non-melanoma skin cancer (NMSC)) 
 
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XIII
 HIV testing and prevention: People who should be offered an HIV test (NICE and BHIVA guidelines); Offering and 
providing hepatitis B and C tests (NICE guidance) and BHIVA guidelines for routine investigation and monitoring of 
adult HIV-1-infected individuals www.bhiva.org/documents/Guidelines/Monitoring/160606-Monitoring-gl-draft-for-
Consultation.pdf  
XIV
 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/559469/VZIG_ChickenPox_v4.pdf 
XV
 NICE guidelines. Tuberculosis NG33 https://www.nice.org.uk/guidance/ng33 
Biologic therapy and infections 
R36 Assess people with psoriasis prior to, and during treatment with, biologic therapy with 
respect to: 
 risk factors for infection (for example, co-morbidities, co-therapy, lifestyle and 
travel) 
 known infections (past or current) 
 signs or symptoms suggestive of infection 
 
Biologic therapy and chronic viral infections – hepatitis B, hepatitis C and HIV  
R37 Test for hepatitis B (surface antigen and core antibody), hepatitis C (IgG) and HIV (HIV-1 
and HIV-2 antibody and HIV-1 antigen) infection in people starting biologic therapy 
 
R38 Consider ongoing screening (for example annually) for hepatitis B, hepatitis C and HIV, 
particularly in people who belong to a group at increased risk of infectionXIII (see Toolkit B: 
Groups at increased risk of tuberculosis, hepatitis B, hepatitis C and HIV, in Supporting 
information 2) 
 
R39 
 
Retest for viral hepatitis in any person who develops unexplained transaminitis (raised 
ALT and/or AST); retest for HIV infection in any person who has symptoms of HIV 
seroconversion.  
 
R40 Consult a hepatitis specialist when treating all people with biologic therapy who have 
hepatitis B or C infection, whether newly-diagnosed or previously known 
 
R41 Provide treatment options to people with psoriasis who are HIV seropositive on a case-
by-case basis; be aware that severe psoriasis can occur in people with uncontrolled HIV 
infection. Involve relevant specialists and ensure HIV viral load is suppressed on ART 
before considering biologic therapy. 
 
R42 Test for varicella zoster (VZ) virus antibody in people with a negative or uncertain history 
for chickenpox; consider varicella vaccination in those who are not varicella-immune and 
seek expert advice.  Be aware of the indications for using VZ immunoglobulin in VZ-
susceptible individuals.XIV 
GPP 
(Good 
Practice 
Point) 
Use of biologic therapy and TB 
R43 Screen for latent TB with an interferon-gamma release assay.  Arrange a plain chest 
radiograph to rule out abnormalities at baseline including granulomas indicative of prior 
infection and other confounding lung diseases. If positive, assess for active TB and/or 
management of latent TB in consultation with a TB specialist (see Tuberculosis NICE 
guidelineXV) 
 
R44 In people who require treatment for latent TB (3 months of isoniazid (with pyridoxine) 
and rifampicin, or 6 months of isoniazid (with pyridoxine)) aim to complete 2 months’ 
treatment before commencing biologic therapy 
 
R45 Any symptoms or signs suggestive of TB, or new exposure to TB or prolonged residence in 
a high-incidence setting should prompt further clinical assessment and investigation, 
including a repeat interferon-gamma release assay. Be aware that active TB on TNF 
 
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XVI
 https://www.gov.uk/drug-safety-update/tumour-necrosis-factor-alpha-inhibitors   
XVII
 www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book 
XVIII
 www.bad.org.uk/leaflets 
XIX
 Loss or reduction of vision in one eye with painful eye movements; double vision; ascending sensory disturbance 
and/or weakness; problems with balance, unsteadiness or clumsiness; altered sensation travelling down the back and 
sometimes into the limbs when bending the neck forwards (Lhermitte's symptom); please see NICE guidelines CG186 
www.nice.org.uk/guidance/cg186  
XX
 Please see NICE Pathway https://pathways.nice.org.uk/pathways/chronic-heart-
failure#path=view%3A/pathways/chronic-heart-failure/diagnosing-and-assessing-chronic-heart-
failure.xml&content=view-node%3Anodes-history-examination-and-referral  
antagonist therapy is often disseminated and extrapulmonary; symptoms may include 
unexplained weight loss, night sweats, non-resolving cough, haemoptysis and 
lymphadenopathy. 
R46 Inform people that they should seek medical advice if symptoms of tuberculosis develop 
during or after treatment with a biologic therapy and issue a patient alert card in line with 
MHRA guidance)XVI 
 
Biologics and vaccination 
R47 Do not give live vaccines to people on biologic therapy or to infants (up to 6 months of 
age) whose mothers have received biologic therapy beyond 16 weeks’ gestation 
 
R48 Stop biologic therapy for at least 6 months before giving live vaccines, and for 12 months 
in the case of Shingles (herpes zoster) vaccine. In general, biologic therapy can be started 
4 weeks after administration of a live vaccine. Refer to the drug-specific SPC and Green 
Book (Immunisation against infectious disease)XVII for further information. 
 
R49 Provide people on biologic therapy information on safe use of vaccinations including 
which vaccination should be used and which to avoid (see BAD Patient Information 
Leaflet on immunisationXVIII and the Green Book,XVII with reference to the clinical risk 
category ‘immunosuppression’)  
 
R50 Where possible, complete all required vaccinations prior to initiation of biologic therapy 
and review vaccination requirements during therapy with reference to the Green BookXVII 
and the clinical risk category ‘immunosuppression’ 
 
Important contraindications to biologic therapies (Good Practice Point, GPP) 
R51 
 
Do not use TNF antagonists in people with demyelinating diseases and review alternative 
interventions in people who have an affected first-degree relative with demyelinating 
disease 
GPP 
R52 Stop treatment and seek specialist advice if neurological symptoms suggestive of 
demyelinating diseaseXIX develop during TNF antagonist therapy  
GPP 
R53 
 
Avoid TNF antagonist therapy in people with severe (NYHA class III and IV) cardiac failure  
GPP 
R54 
 
Assess people with well-compensated (NYHA class I and II) cardiac failureXX and consult 
with a cardiology specialist before using TNF antagonist therapy 
GPP 
R55 
 
Stop TNF antagonist therapy in the event of new or worsening pre-existing heart failure 
and seek specialist advice 
GPP 
R56 Exercise caution and consult a gastroenterology specialist before using secukinumab or 
ixekizumab in people with inflammatory bowel disease 
GPP 
R57 In people undergoing elective surgery balance the potential benefit of preventing post- 
operative infection by stopping biologic therapy against the risk of developing severe or 
unstable disease.  Advise stopping biologic therapy 3 to 5 times the half-life of the drug in 
GPP 
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Table 2. List of key recommendations 
 
ALGORITHM 
 
  
question (see Toolkit A: Summary of licensed indications and posology for biologic 
therapy, in Supporting information 2) or the length of the treatment cycle (whichever is 
longer) between the last dose of therapy and the planned surgery. Inform the surgical 
team that the patient may be at a higher risk of infection post-operatively. Restart 
biologic therapy postoperatively if there is no evidence of infection and wound healing is 
satisfactory. 
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NOTES 
1. Take into account psoriasis factors (the goal of therapy e.g. PGA clear/nearly clear; disease 
phenotype and pattern of activity; disease severity and impact; presence of psoriatic arthritis; 
outcomes of previous treatment for psoriasis) and other factors (age; past or current co-morbid 
conditions; conception plans; body weight). 
2. Take into account both psoriasis and psoriatic arthritis before initiating or making changes to 
biologic therapy, and manage treatment in consultation with a rheumatologist; be aware that the 
presence of and phenotype of psoriatic arthritis (for example, peripheral versus axial disease) may 
influence access to, choice and dose of, biologic therapy. 
3. Consider changing to an alternative biologic therapy if any of the following applies: the psoriasis 
does not achieve the minimum response criteria (primary failure – see R11) or the psoriasis initially 
responds but subsequently loses this response (secondary failure)  
4. Consider escalating the dose of biologic therapy in adults (R22) when an inadequate primary 
response may be due to insufficient drug dosing (for example, in people who are obese or whose 
psoriasis relapses during the treatment cycle). Take into account that dose escalation may be 
associated with an increased risk of infection, and, depending on the drug, off-licence and not 
funded. Currently, a dose-escalation strategy is not applicable to secukinumab or ixekizumab. 
5. This guidance applies to biosimilars, subject to recommendations given within the BAD position 
statement and EMA guidelines.4,5 
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DECISION AID 
This table supports the decision-making process during the consultation for patients and clinicians before the initiation of biologic therapy. It is complementary to 
the existing patient information leaflets (PILs; www.bad.org.uk/leaflets). All biologic therapies for the treatment of psoriasis require bloods tests before and during 
treatment. If you have psoriatic arthritis, your doctor will take this into consideration. 
Frequently Asked 
Questions 
Adalimumab Etanercept Infliximab Ixekizumab Secukinumab Ustekinumab No active 
treatment 
How often do I 
need to inject the 
treatment? 
1 injection under 
the skin 
Every other week 
1 injection under 
the skin  
Once or twice a 
week 
1 injection in the 
vein  
 
Every 8 weeks 
1 injection under 
the skin 
Every 2 weeks for 
the first 3 
months, every 4 
weeks thereafter 
2 injections under 
the skin 
Every 4 weeks 
1 injection under 
the skin 
Every 12 weeks 
Does not apply 
Who gives the 
treatment? 
You or your carer 
will learn to give 
the injection after 
training.  
You or your carer 
will learn to give 
the injection after 
training. 
You will need to 
go to hospital 
where the 
injection will be 
given by a 
healthcare 
professional.  
You or your carer 
will learn to give 
the injection after 
training 
You or your carer 
will learn to give 
the injection after 
training. 
You may choose 
to have the 
injection given to 
you by a nurse in 
your home. 
Alternatively, you 
or your carer may 
learn to give the 
injection after 
training. 
Does not apply 
How long has this 
treatment been 
around for? 
Since 2008 Since 2004 Since 2006 Anticipated to be 
available in 2017 
Since 2015 Since 2009 Does not apply 
How many 
people become 
clear or nearly 
clear of psoriasis 
because of this 
treatment?XXI 
Around 341 per 
1000 people after 
3-4 months of 
treatment6 
Around 227 per 
1000 people after 
3-4 months of 
treatment6 
Around 451 per 
1000 people after 
3-4 months of 
treatment6 
Around 682 per 
1000 people after 
3-4 months of 
treatment6 
Around 579 per 
1000 people after 
3-4 months of 
treatment6 
Around 413 per 
1000 people after 
3-4 months of 
treatment6 
Roughly 20 per 
1000 people 
become clear or 
nearly clear with 
placebo (sham 
injection) after 3-
4 months6 
                                                          
XXI
 The evidence is drawn from clinical trials including a mixed biologic-naïve and experienced population 
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In U.K. clinical 
practice, what 
are the chances 
of staying on this 
treatment past 1 
year?XXII 
77-81% chance7 67-73% chance7 54-74% chance7 Not known at 
present 
Not known at 
present  
86-92% chance7 Does not apply 
How many 
people 
experience 
unwanted effects 
that are serious 
enough to stop 
the treatment?XXI, 
XXIII 
Up to 2 per 1000 
people after 3-4 
months of 
treatment6 
Up to 10 per 1000 
people after 3-4 
months of 
treatment6 
Up to 82 per 1000 
people after 3-4 
months of 
treatment6 
Up to 39 per 1000 
people after 3-4 
months of 
treatment6 
Up to 5 per 1000 
people after 3-4 
months of 
treatment6 
Up to 1 per 1000 
people after 3-4 
months of 
treatment6 
Roughly 19 per 
1000 people 
taking a placebo 
(sham injection) 
withdraw after 3-
4 months of 
monitoring6 
How many 
people 
experience an 
infection serious 
enough to lead to 
admission into 
hospital because 
of this 
treatment?XXIII  
Up to 11 per 1000 
people after 3-4 
months of 
treatment8 
Up to 6 per 1000 
people after 3-4 
months of 
treatment8 
 Up to 41 per 
1000 people after 
5-7 months of 
treatment 
Up to 11 per 1000 
people after 3-4 
months of 
treatment 
Up to 10 per 1000 
people after 3-4 
months of 
treatment8 
Up to 4 per 1000 
people after 3-4 
months of 
treatment8 
Roughly 4 per 
1000 people 
taking a placebo 
(sham injection) 
after 3-4 months 
of monitoring8 
What conditions 
would make your 
doctor hesitant 
about giving you 
the treatment? 
Moderate or 
severe heart 
failure, 
demyelinating 
disorders (e.g. 
multiple sclerosis) 
Moderate or 
severe heart 
failure, 
demyelinating 
disorders (e.g. 
multiple sclerosis) 
Moderate or 
severe heart 
failure, 
demyelinating 
disorders (e.g. 
multiple sclerosis) 
Inflammatory 
bowel disease 
(i.e. Crohn’s 
disease or 
ulcerative colitis), 
recurrent candida 
infection (i.e. 
thrush) 
Inflammatory 
bowel disease 
(i.e. Crohn’s 
disease or 
ulcerative colitis), 
recurrent candida 
infection (i.e. 
thrush) 
No particular 
condition 
Does not apply 
                                                          
XXII
 The evidence is drawn from a real-world UK biologic-naïve population; it may not apply to biologic choice for subsequent lines of treatment 
XXIII
 The figures are drawn from the upper limit of the 95% confidence interval from a meta-analysis of clinical trials and reflect the risk that has been excluded; differences amongst 
biologic therapies should be interpreted with caution 
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What if I want to 
have children? 
Women and men 
have had children 
on this treatment. 
The risk to the 
baby is unknown. 
Your 
dermatologist will 
discuss this with 
you. 
Women and men 
have had children 
on this treatment. 
The risk to the 
baby is unknown. 
Your 
dermatologist will 
discuss this with 
you. 
Women and men 
have had children 
on this treatment. 
The risk to the 
baby is unknown. 
Your 
dermatologist will 
discuss this with 
you. 
The risk to the 
baby is unknown. 
Your 
dermatologist will 
discuss this with 
you. 
The risk to the 
baby is unknown. 
Your 
dermatologist will 
discuss this with 
you. 
The risk to the 
baby is unknown. 
Your 
dermatologist will 
discuss this with 
you. 
During 
pregnancy, 
psoriasis may get 
better, stay the 
same, or become 
worse 
Table 3. Decision aid. NICE eligibility criteria, infliximab: PASI ≥20, DLQI >18; other biologic therapies: PASI ≥10, DLQI >10 
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SUGGESTED SCHEDULE FOR SCREENING AND MONITORING 
  BaselineXXIV MonitoringXXIV 
History/symptom enquiry 
Psoriasis Disease phenotype; course (stable/unstable); response & adverse 
effects to prior therapies  
Yes Ongoing 
Psoriatic arthritis Screen for psoriatic arthritis (e.g. using the PEST 
questionnaireXXV); for people with psoriatic arthritis symptom 
enquiry to assess control 
Yes Every 12 months 
Identification of contraindications to 
therapy and/or development of 
therapy-induced toxicity 
Thorough history, symptom enquiry  Yes Every 3-6 months 
Infection Any past or current chronic infection including tuberculosis, 
candidiasis 
Yes 
Every 3-6 months 
Identify risk factors for tuberculosis, hepatitis B, C and HIVXXVI 
Ascertain history for chickenpox N/A 
Alert cardXXVII Ensure people carry an alert card with them at all times in line 
with MHRA guidance 
Yes At each review appointment 
Cardiovascular assessmentXXVIII 
 
Include symptom enquiry about heart failure 
[NYHA III. Marked limitation of physical activity. Comfortable at rest. 
Less than ordinary activity causes fatigue, palpitation or dyspnea. NYHA 
IV. Unable to carry on any physical activity without discomfort. 
Symptoms of heart failure at rest. If any physical activity is undertaken, 
discomfort increases.] 
Yes Clinical assessment every 3-6 months 
                                                          
XXIV
 Additional assessment and monitoring may be required in patients on concomitant therapy or in certain clinical circumstances 
XXV
 www.bad.org.uk/healthcare-professionals/forms-downloads  
XXVI
 See Toolkit B: Groups at increased risk of tuberculosis, hepatitis B, hepatitis C and HIV, in Supporting information 2 
XXVII
 https://www.gov.uk/drug-safety-update/tumour-necrosis-factor-alpha-inhibitors  
XXVIII
 Evidence of demyelination/heart failure may preclude use of TNF antagonists  
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Neurological assessmentXXVIII Past or current history or symptoms of demyelinating diseaseXXVIII Yes Every 3-6 months 
Gastrointestinal assessmentXXIX Past of current history or symptoms of inflammatory bowel 
disease  
Yes Every 3-6 months 
Malignancy Any past or current malignancy (including skin cancer) 
Yes Every 3-6 months 
Ensure concordant with national cancer screening programmes 
Gynaecological review of patients with history of cervical 
dysplasia 
BADBIR  Offer the opportunity to participate Yes Every 6 months (to complete follow-up 
data) 
Clinical assessments 
Psoriasis disease severity assessment  Goal of therapy, e.g. a PGA of clear or nearly clear 
Yes 
To establish disease response; every 6 
months thereafter 
PASI (or BSA if PASI not applicable) 
DLQI 
Skin cancer  Full skin examination Yes As indicated by risk at baseline and in the 
context of immunosuppression 
Psoriatic arthritis Consult with a rheumatologist Yes To establish disease response; every 3-6 
months thereafter and/or as clinically 
indicated 
General physical examination To identify contra-indications to therapy and/or development of 
therapy-induced toxicity 
Yes As indicated by history/symptom enquiry 
Investigations 
Blood tests Full blood count; creatinine and electrolytes; liver function tests 
Yes 
At 3-4 months; every 6 months thereafter 
and/or as clinically indicated  
Hepatitis B (surface antigen and core antibody) hepatitis C (IgG) If clinically indicated, e.g. transaminitis 
(raised ALT and/or AST), or ongoing 
(annually) in people who belong to a 
                                                          
XXIX
 Exercise caution using secukinumab in people with inflammatory bowel disease 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
group at increased risk of infectionXXVI 
Human immunodeficiency virus (HIV-1 and HIV-2 antibody, and 
HIV-1 antigen) 
If clinically indicated, e.g. symptoms of 
seroconversion, or ongoing (annually) in 
people who belong to a group at 
increased risk of infectionXXVI 
Autoantibodies (anti-nuclear antibodies, anti-nuclear double-
stranded DNA antibodies) 
If symptoms or signs suggest 
development of autoimmune 
phenomena, e.g. transaminitis (raised ALT 
and/or AST) 
Test for varicella zoster virus antibody in people with a negative 
or uncertain history for chickenpox 
Consider varicella vaccination in those 
who are not varicella-immune and seek 
expert advice; be aware of the indications 
for using VZ immunoglobulin in VZ-
susceptible individualsXXX 
Tuberculosis Interferon-gamma release assay and chest X-ray 
 
Yes If clinically indicated, e.g. symptoms or 
signs of tuberculosis, new exposure to 
tuberculosis or residence in high-
incidence setting 
Urine Urine analysis 
Yes If clinically indicated 
Urine pregnancy test 
Table 4. Suggested schedule for screening and monito
                                                          
XXX
 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/559469/VZIG_ChickenPox_v4.pdf  
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AUDIT STANDARDS, DATA ITEMS AND DATA COLLECTION METHODOLOGY  
Dermatology teams involved in prescribing biologic interventions should use audit as a tool to monitor their 
service against national guidelines of care. The aim should be to ensure that the service is high in quality, 
safe and cost-effective. See Toolkit C: Audit standards, data items and data collection methodology, in 
Supporting information 2, for further details.  
 
STAKEHOLDER INVOLVEMENT AND PEER REVIEW 
The full version of the guideline was made available to the BAD membership, British Society for Paediatric 
Dermatology, British Dermatological Nursing Group, Primary Care Dermatological Society, British Society 
for Paediatric and Adolescent Rheumatology, British Society of Rheumatology, Royal College of Obstetrics 
and Gynaecology, Psoriasis and Psoriatic Arthritis Alliance, Psoriasis Association and relevant 
pharmaceutical companies (see Appendix F, in Supporting information 1, for the full list of stakeholders), 
comments from whom were actively considered by the GDG. Following further review, the finalized version 
was peer-reviewed by the Clinical Standards Unit of the BAD, made up of the Therapy & Guidelines Sub-
committee (T&G), prior to submission for publication. 
 
LIMITATIONS OF THE GUIDELINE  
This document has been prepared on behalf of the BAD and is based on the best data available when the 
document was prepared. It is recognized that under certain conditions it may be necessary to deviate from 
the guidelines and that the results of future studies may require some of the recommendations herein to 
be changed. Failure to adhere to these guidelines should not necessarily be considered negligent, nor 
should adherence to these recommendations constitute a defence against a claim of negligence. Limiting 
the review to English language references was a pragmatic decision but the authors recognize this may 
exclude some important information published in other languages. 
 
PLANS FOR GUIDELINE REVISION  
This 2017 guideline updates the previous version.9 An annual literature review is planned for this fast-
moving subject and the recommendations updated where necessary, in line with the BAD’s recommended 
guideline development methodology.1 
 
SUPPORTING INFORMATION 
The full version of this guideline is available in the online Supporting information 1 document, which 
includes tables linking evidence to recommendations (LETR), details of the network meta-analysis, 
summary of included studies, forest plots, GRADE evidence profiles, PRISMA flow diagrams, list of excluded 
studies and search strategies. Supporting information 2 contains toolkits to aid implementation. 
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